Strain/modification/intervention | SS-like phenotypea | Remarksa | Reference |
---|---|---|---|
(NZB/NZW)F1 | SG and LG infl. | SLE-like disease | [19] |
IFA | ↑ SG infl., ↓ SG function, anti-Ro | ↑ DC numbers early in the disease process | [22] |
Anti-CD25 | ↑ SG infl., anti-Ro | ↑ ANA | [23] |
Poly(I:C) | ↓ SG function (transient) | Role of TLR3 engagement | [24] |
NOD | SG and LG infl., ↓ SG and LG function | T1D, multiple immune system-related alterations | [12] |
scid | No SG infl., ↑ SG function | Abnormal salivary gland physiology remains | [60] |
Igμ null | ↑ SG function | Insulitis but no progression to overt T1D | [64] |
ll4-/- | ↑ SG function | Absence of anti-M3R IgG1 | [77] |
Ifnγ-/- | No SG infl., ↑ SG function, ↑ LG infl. | Retained LG infl. | [78] |
IfnγR-/- | No SG infl., ↑ SG function, ↑ LG infl. | Retained LG infl. | [78] |
Tnfr1-FcIgG 3 Tg | ↓ SG and LG infl. | Insulitis but no progression to overt T1D | [75] |
Ica69-/- | ↓ SG and LG infl. | Unchanged incidence rate of T1D | [61] |
Aire-/- | ↑ LG infl., ↓ LG function | Role of OBP1a and central tolerance | [63] |
NZW-Ssial3 | ↓ SG infl., SG function unchanged | Unchanged insulitis score | [55] |
E2f1-/- | ↑ SG infl., ↓ SG function | ↑ T1D, ↓ Tregs | [58] |
Hsp60 | ↓ SG infl., ↑ SG function | Biomarkers in saliva predict treatment success | [57] |
Hsp60 amino acids 437 to 460 | ↓ SG infl., ↑ SG function | Biomarkers in saliva indicate SG function | [57] |
LTβR-Ig | Arrested progression of SG infl. | Changes in cellular composition of SG infl. | [48] |
Anti-VCAM1 | ↓ LG infl. | LG function, SG infl. and SG function not assessed | [76] |
Anti-α4-integrin | ↓ LG infl. | LG function, SG infl. and SG function not assessed | [76] |
Anti-PNAd | ↓ LG infl. | LG function, SG infl. and SG function not assessed | [76] |
Anti-L-selectin | ↓ LG infl. | LG function, SG infl. and SG function not assessed | [76] |
Anti-LFA1 | ↓ LG infl. | LG function, SG infl. and SG function not assessed | [76] |
Il10 | ↓ SG infl., ↑ SG function | Retrograde gene delivery through SG ducts | [96] |
Tnfr1-Ig | ↓ SG function | Retrograde gene delivery through SG ducts | [74] |
NOD-H2b | SG and LG infl., ↓ SG and LG function | No T1D | [42] |
ll4-/- | ↑ SG function | Absence of anti-M3R IgG1 | [65] |
C.Stat6-/- | ↑ SG function | Absence of anti-M3R IgG1 | [66] |
NOD-scid | No SG infl., normal SG function | Abnormal salivary gland physiology remains | [60] |
Ifnγ-/- | No SG and LG infl., ↑ SG function | Improved salivary gland physiology | [78] |
E2f1-/- | No SG infl., retained ↓ SG function | Effect of E2F1 deficiency on SG development | [59] |
C57BL/6.NOD-Aec1Aec2 | SG and LG infl. ↓ SG and LG function | Increased applicability compared with NOD mice | [41] |
C3-/- | No SG and LG infl., ↑ SG function | Assessing the role of C3 | [88] |
Il17r:Fc | ↓ SG infl., ↑ SG function | Retrograde gene delivery through SG ducts | [81] |
C57BL/6 | May develop SG infl. at an old age | Widely used recipient strain | |
Il17a | SG infl., ↓ SG function | Retrograde gene delivery through SG ducts | [80] |
C57BL/6-Il14α Tg | SG infl., ↓ SG function | High incidence of CD5+ lymphoma, nephritis | [101] |
Ltα -/- | ↓ SG infl., ↑ SG function | LTα-dependent disease phenotype | [104] |
C57BL/6-Id3-/- | SG and LG infl., ↓ SG function, anti-Ro and La | Exocrine gland dysfunction precedes SG and LG infl. | [125] |
Anti-CD20 | ↓ SG and LG infl., ↑ SG function | Depletion of B cells | [127] |
C57BL/6-Baff Tg | SG and LG infl., ↓ SG function | MZ B-cell dominated infl., SLE-like disease | [106] |
Ltβ-/- | ↓ SG infl., ↑ SG function | MZ B-cell dependence of the SS-like disease | [107] |
Tnfα-/- | Unchanged | Increased incidence of B-cell lymphoma | [110] |
BALB/c-Act1-/- | SG and LG infl., anti-Ro and anti-La | MZ B-cell dominated infl., SLE-like disease | [115] |
CD40-/- | SG and LG infl. unchanged | Absence of anti-Ro and anti-La | [115] |